| scholarly article | Q13442814 |
| P50 | author | Jean-Robert Ioset | Q124670633 |
| Marcel Kaiser | Q30347237 | ||
| P2093 | author name string | Louis Maes | |
| Thomas Spangenberg | |||
| Leela Pavan Tadoori | |||
| P2860 | cites work | Targeting Trypanothione Metabolism in Trypanosomatid Human Parasites | Q37782110 |
| Folate metabolism in human malaria parasites--75 years on. | Q38090355 | ||
| Lead- and drug-like compounds: the rule-of-five revolution | Q38225014 | ||
| A comparison of three methods of estimating EC50 in studies of drug resistance of malaria parasites | Q39085081 | ||
| The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T.b. rhodesiense and T.b. gambiense) in vitro | Q39416311 | ||
| Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). | Q39436993 | ||
| Drug resistance in leishmaniasis | Q41271991 | ||
| Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity | Q41824183 | ||
| Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures | Q42152987 | ||
| 2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase | Q44615883 | ||
| Thousands of chemical starting points for antimalarial lead identification | Q24289329 | ||
| Imaging of Plasmodium Liver Stages to Drive Next-Generation Antimalarial Drug Discovery | Q27861956 | ||
| Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis | Q28271849 | ||
| Tolerance and safety of nifurtimox in patients with chronic chagas disease | Q28295159 | ||
| Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial | Q28475917 | ||
| Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51 | Q28481694 | ||
| Isothermal microcalorimetry, a new tool to monitor drug action against Trypanosoma brucei and Plasmodium falciparum | Q28484117 | ||
| The open access malaria box: a drug discovery catalyst for neglected diseases | Q28533977 | ||
| Orally active antischistosomal early leads identified from the open access malaria box | Q28538566 | ||
| New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays | Q29615588 | ||
| Chemical genetics of Plasmodium falciparum | Q29617272 | ||
| Identification of Cryptosporidium parvum active chemical series by Repurposing the open access malaria box | Q30486772 | ||
| Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase. | Q31152213 | ||
| Identification and optimization of an aminoalcohol-carbazole series with antimalarial properties | Q33636074 | ||
| Use of isothermal microcalorimetry to monitor microbial activities. | Q34020076 | ||
| Leishmaniasis: an update of current pharmacotherapy | Q34318765 | ||
| Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections | Q34975777 | ||
| Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. | Q36477657 | ||
| Pharmacokinetics, Trypanosoma brucei gambiense efficacy, and time of drug action of DB829, a preclinical candidate for treatment of second-stage human African trypanosomiasis | Q37263574 | ||
| Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities | Q37404837 | ||
| Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development | Q37732551 | ||
| P433 | issue | 5 | |
| P921 | main subject | malaria | Q12156 |
| Trypanosomatidae | Q132954 | ||
| P304 | page(s) | 634-645 | |
| P577 | publication date | 2015-02-17 | |
| P1433 | published in | Journal of Biomolecular Screening | Q6294856 |
| P1476 | title | Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids | |
| P478 | volume | 20 |
| Q58755706 | 4-Phenyl-1,3-thiazole-2-amines as scaffolds for new antileishmanial agents |
| Q39521863 | 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis. |
| Q37629375 | A novel in vitro image-based assay identifies new drug leads for giardiasis. |
| Q30488470 | Antileishmanial Activity of Compounds Derived from the Medicines for Malaria Venture Open Access Box Against Intracellular Leishmania major Amastigotes |
| Q46338517 | Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides |
| Q28550778 | Bilayer Effects of Antimalarial Compounds |
| Q28821118 | Biological characterization of chemically diverse compounds targeting the Plasmodium falciparum coenzyme A synthesis pathway |
| Q47381598 | Characterization of Plasmodium Atg3-Atg8 interaction inhibitors identifies novel alternative mechanisms of action in Toxoplasma gondii. |
| Q39011875 | Chemotherapy of leishmaniasis: present challenges |
| Q91717413 | Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness |
| Q61855920 | Cyclic Nucleotide-Specific Phosphodiesterases as Potential Drug Targets for Anti-Leishmania Therapy |
| Q36000826 | Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes |
| Q51730628 | Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. |
| Q36053050 | Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by Rational Target-Focused Repurposing Approaches. |
| Q48330948 | Discovery of novel, orally bioavailable, antileishmanial compounds using phenotypic screening. |
| Q56891264 | Evolve and survive |
| Q30788575 | Extensive Shared Chemosensitivity between Malaria and Babesiosis Blood-Stage Parasites |
| Q60031608 | High Throughput and Computational Repurposing for Neglected Diseases |
| Q28551393 | Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade. |
| Q37358648 | Metabolomic Profiling of the Malaria Box Reveals Antimalarial Target Pathways |
| Q27826351 | Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond |
| Q38782578 | Rapid Chagas Disease Drug Target Discovery Using Directed Evolution in Drug-Sensitive Yeast |
| Q57167324 | Repurposing Strategy of Atorvastatin against Trypanosoma cruzi: Monotherapy and Combined Therapy with Benznidazole Exhibit Synergistic Trypanocidal Activity |
| Q28550703 | Screening of the Open Source Malaria Box Reveals an Early Lead Compound for the Treatment of Alveolar Echinococcosis |
| Q38695331 | Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery. |
| Q28552326 | Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni |
| Q48022900 | Targeted Phenotypic Screening in Plasmodium falciparum and Toxoplasma gondii Reveals Novel Modes of Action of Medicines for Malaria Venture Malaria Box Molecules. |
Search more.